Legend Biotech Corporation (LEGN) Stock Price & How to Invest
Short answer
LEGN is Legend Biotech, a commercial-stage cell-therapy company whose value rests almost entirely on CARVYKTI, the BCMA-directed CAR-T for multiple myeloma it co-develops and shares profits on with Johnson & Johnson. Investing in it means betting that CARVYKTI keeps scaling toward blockbuster status and that Legend converts near-breakeven into durable profit.
LEGN stock price
As of 2026-07-08, Legend Biotech Corporation (LEGN) last closed at $27.87, down 29.4% over the past year. Over the past 52 weeks it has traded between $16.65 and $44.32.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Legend Biotech Corporation's investor relations page. Walnut is informational, not investment advice.
What does Legend Biotech Corporation (LEGN) do?
Legend Biotech is a global cell-therapy company best known for CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. It develops and commercializes CARVYKTI in a 50/50 profit-and-cost-sharing collaboration with Johnson & Johnson, so Legend's reported revenue shows up largely as collaboration and license income rather than direct product sales. The company also runs an earlier-stage pipeline of other cell therapies and solid-tumor programs, but CARVYKTI drives essentially all of the current commercial narrative.
The investment picture is a scaling-into-profitability story. CARVYKTI reached roughly $1.9 billion in global net trade sales in 2025 and grew about 62 percent year over year in the first quarter of 2026, helped by earlier-line use and expanded manufacturing across more than 300 treatment sites. Legend has been narrowing its losses toward adjusted breakeven while holding a sizable cash cushion, but it remains dependent on one franchise, on J&J as its commercial partner, and on a competitive multiple-myeloma market. The stock trades as a high-multiple growth biotech, so results and the pace toward sustained profit matter a great deal.
What's driving Legend Biotech Corporation (LEGN)?
1. CARVYKTI commercial ramp
CARVYKTI net trade sales reached about $1.9 billion in 2025 and rose roughly 62 percent year over year in Q1 2026, with ex-US sales growing far faster than US sales off a smaller base. The franchise is now available in 18 markets and more than 300 sites, and management has pointed to expanding manufacturing capacity as the key throughput lever. Continued volume growth is the single largest driver of the story.
2. Move to earlier lines of therapy
Approvals expanding CARVYKTI into earlier treatment lines widen the eligible patient pool well beyond heavily pretreated patients. Earlier use, if supported by durable outcomes data, is what supports the multibillion-dollar sales trajectory analysts model. Adoption depends on physician comfort with CAR-T logistics versus off-the-shelf alternatives.
3. Path to profitability
Legend narrowed its net loss substantially in Q1 2026 (adjusted net loss of about $10.5 million) and reported a full-year 2025 adjusted net loss of roughly $33 million, signaling it is approaching adjusted breakeven. The J&J profit split means margin leverage builds as CARVYKTI scales. Reaching and sustaining GAAP profit remains the central proof point investors are watching.
4. Pipeline optionality
Beyond CARVYKTI, Legend is advancing earlier-stage cell therapies including next-generation and solid-tumor programs. These are largely unproven and years from meaningful revenue, so they function as long-dated optionality rather than a current earnings contributor. Any clinical readout that de-risks a second franchise would matter given the current single-product concentration.
What are the risks to Legend Biotech Corporation (LEGN)?
Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. The multiple-myeloma market is increasingly crowded, with competing CAR-T therapies like Bristol Myers Squibb's Abecma and off-the-shelf BCMA bispecific antibodies such as J&J's Tecvayli and Pfizer's Elrexfio that avoid CAR-T's manufacturing and logistics burden. CAR-T therapies also carry serious safety considerations and manufacturing and capacity constraints that can cap growth. The company is only near breakeven and still posts losses, so any sales miss, pricing pressure, or safety signal can move the stock sharply. As a China-founded, US-listed ADR, it also carries geopolitical, supply-chain, and regulatory exposure that pure-play US biotechs do not.
How is Legend Biotech Corporation (LEGN) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Legend Biotech Corporation's investor relations page or your broker.
- Revenue (TTM, collaboration/license): ~$1.1B
- CARVYKTI net trade sales (FY2025, global): ~$1.9B
- Q1 2026 total revenue: ~$305M
- FY2025 adjusted net loss: ~$33M
- Cash & time deposits (Q1 2026): ~$835M
- Market cap: ~$5.8B
LEGN trades as a high-multiple growth biotech whose revenue is recognized mainly as collaboration and license income under the J&J profit split, distinct from CARVYKTI's roughly $1.9 billion in 2025 global net trade sales. The company is approaching adjusted breakeven while still reporting losses, so the valuation reflects expectations for continued CARVYKTI growth rather than current earnings. Wall Street price targets vary widely, underscoring how much hinges on the pace of the ramp.
Who competes with Legend Biotech Corporation (LEGN)?
Competing CAR-T therapies
Bristol Myers Squibb and 2seventy bio's Abecma (idecabtagene vicleucel) is the other approved BCMA CAR-T in multiple myeloma and the most direct head-to-head, competing on efficacy, safety, and slot availability at treatment centers.
Off-the-shelf BCMA bispecifics and ADCs
BCMA-targeting bispecific antibodies like J&J's Tecvayli (teclistamab) and Pfizer's Elrexfio (elranatamab), plus GSK's antibody-drug conjugate Blenrep, offer off-the-shelf dosing that sidesteps CAR-T's manufacturing wait and logistics, and are being pushed into earlier lines.
Large oncology and cell-therapy developers
Big pharma and biotech players in blood-cancer immunotherapy, including partner-turned-rival dynamics at Johnson & Johnson and broader CAR-T developers like Gilead's Kite unit and Novartis, shape pricing, trial design, and the competitive standard of care.
How to invest in Legend Biotech Corporation (LEGN)
There are three common ways to get LEGN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so LEGN sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where LEGN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Legend Biotech Corporation (LEGN)
LEGN is effectively a one-product CAR-T story riding CARVYKTI's ramp with J&J, so the payoff and the risk both hinge on that single franchise.
More on Legend Biotech Corporation (LEGN)
Whether LEGN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LEGN a buy?, and where the stock could go from here in the LEGN stock forecast.
For income investors, whether LEGN pays a dividend and how the payout looks is covered in does LEGN pay a dividend?
Build a basket around LEGN with Walnut
Use Legend Biotech Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Legend Biotech do?
+
Legend Biotech is a cell-therapy company whose flagship product is CARVYKTI, a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. It co-develops and shares profits on CARVYKTI with Johnson & Johnson and runs an earlier-stage pipeline of other cell therapies.
Is LEGN a US-listed stock?
+
Yes. Legend Biotech trades on the Nasdaq under the ticker LEGN as an American Depositary Receipt. The company was founded in China and is legally domiciled outside the US, which adds ADR and geopolitical considerations for investors.
What is CARVYKTI and why does it matter so much?
+
CARVYKTI (cilta-cel) is a personalized CAR-T therapy that reengineers a patient's own T cells to attack BCMA-expressing myeloma cells. It generated roughly $1.9 billion in global net trade sales in 2025 and is essentially the entire commercial story, so its trajectory drives the stock.
How does Legend make money from CARVYKTI?
+
Legend shares CARVYKTI's costs and profits with Johnson & Johnson under a collaboration. As a result, its reported revenue appears largely as collaboration and license income rather than direct product sales, and it captures roughly half of the franchise economics.
Is Legend Biotech profitable?
+
Not yet on a GAAP basis, but it is close to adjusted breakeven. It reported a full-year 2025 adjusted net loss of about $33 million and narrowed its Q1 2026 adjusted net loss to roughly $10.5 million as CARVYKTI sales scaled.
Who competes with CARVYKTI?
+
Its closest rival is Bristol Myers Squibb's Abecma, the other approved BCMA CAR-T. It also faces off-the-shelf BCMA bispecific antibodies like J&J's Tecvayli and Pfizer's Elrexfio, plus GSK's ADC Blenrep, which avoid CAR-T's manufacturing wait.
What are the biggest risks for LEGN?
+
Concentration in a single product and a single partner, a crowded multiple-myeloma market, CAR-T manufacturing and capacity constraints, serious safety considerations, ongoing losses, and ADR-related geopolitical and regulatory exposure are the main risks that can move the stock sharply.
How can I invest in LEGN through Walnut?
+
You can add LEGN to a thematic basket in Walnut, connect your brokerage, and place orders that bring the basket toward your target weights. Walnut is not an investment adviser, so any decision to buy or sell LEGN is your own.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Legend Biotech Corporation's investor relations page or your broker before making investment decisions.